SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. The study is being done in the lab of Dr. Kiminobu Sugaya PhD, Head of Neuroscience, Burnett School of Biomedical Sciences, University of Central florida, Orlando, Florida. Dr. Sugaya and his research team are developing a more effective way to treat GBM, an aggressive, incurable form of brain cancer.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
Ludwig Announces Patent Filing for Breakthrough in Identifying mRNA Genes
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Ludwig Enterprises Appoints Scott Silverman as CFO
Ludwig Enterprises Announces Effectiveness of Form S-1 Registration Application
SPARKS, NV / ACCESSWIRE / April 12, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company) is proud to announce that its flagship nutraceutical, NuGenea™ launch will be forthcoming.
SPARKS, NV / ACCESSWIRE / March 21, 2023 / Ludwig Enterprises, Inc., OTC:LUDG, (Ludwig - The Genomics Language Company ™) is pleased to announce it intends in the second quarter of 2023 to file a Non-Offering Prospectus to enable the Company to be listed on the Canadian Stock Exchange (CSE).